Doris E Payer
Overview
Explore the profile of Doris E Payer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
310
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boileau I, Mansouri E, Williams B, Le Foll B, Rusjan P, Mizrahi R, et al.
Biol Psychiatry
. 2016 Jun;
80(9):691-701.
PMID: 27345297
Background: One of the major mechanisms for terminating the actions of the endocannabinoid anandamide is hydrolysis by fatty acid amide hydrolase (FAAH), and inhibitors of the enzyme were suggested as...
2.
Okita K, Ghahremani D, Payer D, Robertson C, Dean A, Mandelkern M, et al.
Drug Alcohol Depend
. 2016 Feb;
161:163-70.
PMID: 26880595
Background: Individuals who use methamphetamine chronically exhibit emotional and dopaminergic neurochemical deficits. Although the amygdala has an important role in emotion processing and receives dopaminergic innervation, little is known about...
3.
Payer D, Guttman M, Kish S, Tong J, Adams J, Rusjan P, et al.
Neurology
. 2016 Jan;
86(3):224-30.
PMID: 26718579
Objective: To investigate whether levodopa-induced dyskinesias (LID) are associated with D3 overexpression in levodopa-treated humans with Parkinson disease (PD). Methods: In this case-control study, we used PET with the D3-preferring...
4.
Okita K, Ghahremani D, Payer D, Robertson C, Mandelkern M, London E
Int J Neuropsychopharmacol
. 2015 Dec;
19(5).
PMID: 26657175
Background: Individuals with substance-use disorders exhibit emotional problems, including deficits in emotion recognition and processing, and this class of disorders also has been linked to deficits in dopaminergic markers in...
5.
Payer D, Park M, Kish S, Kolla N, Lerch J, Boileau I, et al.
Front Hum Neurosci
. 2015 Sep;
9:472.
PMID: 26379535
Personality disorder symptomatology (PD-Sx) can result in personal distress and impaired interpersonal functioning, even in the absence of a clinical diagnosis, and is frequently comorbid with psychiatric disorders such as...
6.
Payer D, Guttman M, Kish S, Tong J, Strafella A, Zack M, et al.
Mov Disord
. 2015 Feb;
30(2):160-6.
PMID: 25641350
Dopamine agonist medications with high affinity for the D3 dopamine receptor are commonly used to treat Parkinson's disease, and have been associated with pathological behaviors categorized under the umbrella of...
7.
Wing V, Payer D, Houle S, George T, Boileau I
Neuropsychopharmacology
. 2014 Dec;
40(6):1417-27.
PMID: 25502631
Striatal dopamine (DA) is thought to have a fundamental role in the reinforcing effects of tobacco smoking and nicotine. Microdialysis studies indicate that nicotine also increases DA in extrastriatal brain...
8.
Payer D, Behzadi A, Kish S, Houle S, Wilson A, Rusjan P, et al.
Neuropsychopharmacology
. 2013 Aug;
39(2):311-8.
PMID: 23921256
The dopamine system is a primary treatment target for cocaine dependence (CD), but research on dopaminergic abnormalities (eg, D2 receptor system deficiencies) has so far failed to translate into effective...
9.
Payer D, Baicy K, Lieberman M, London E
Emotion
. 2012 Apr;
12(2):229-35.
PMID: 22468617
Emotion regulation can be achieved in various ways, but few studies have evaluated the extent to which the neurocognitive substrates of these distinct operations overlap. In the study reported here,...
10.
Payer D, Dean A, Boileau I
Neuropsychopharmacology
. 2012 Mar;
37(5):1081-2.
PMID: 22419225
No abstract available.